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Only a few natural products possessing a diazeniumdiolate have been 
isolated and usually these compounds display a broad range of 
biological activities. Only recently the first diazeniumdiolate natural 
product biosynthetic gene cluster was identified in Burkholderia 
cenocepacia H111, which produces the fungicide (–)-fragin and the 
signal molecule (rac)-valdiazen. In this study, L-valine was identified 
as the initial substrate of (–)-fragin biosynthesis by feeding 
experiments using isotopically labeled amino acids. The formation of 
the diazeniumdiolate was chemically studied by several proposed 
intermediates. Our results indicate that the functional group is formed 
during an early stage of the biosynthesis. Furthermore, an oxime 
compound was identified as a degradation product of (–)-fragin and 
was also observed in the crude extract of the wild type strain. 
Moreover, a structure-activity relationship analysis revealed that each 
moiety of (–)-fragin is essential for its biological activity. 
The diazeniumdiolate moiety is a fascinating functional group 
containing two O- and two N-atoms,[1,2] and compounds with this 
group have been discovered already more than two centuries 
ago.[3] In 1966, the first natural product possessing a 
diazeniumdiolate group was isolated from Streptomyces 
alanosinicus and named alanosine.[4] This compound displayed 
strong antiviral and antitumor activity, and reached a phase II 
clinical study for its potent antimetabolite activity.[5] Since this 
discovery, only a few new diazeniumdiolate natural products have 
been identified,[6] such as e.g. (–)-fragin (1), which was isolated 
from the culture supernatant of Pseudomonas fragi. This 
compound was shown to possess antifungal, antitumor, 
antibacterial, and plant growth inhibitory activities.[7-11] More 
recently, the novel signaling molecule (rac)-valdiazen (2) was 
isolated from B. cenocepacia H111 (H111) using a metagenomic 
approach,[12-14] and Hertweck and co-workers discovered in the 
same year a new family of diazeniumdiolate siderophores[15,16]. 
The discovery of (rac)-valdiazen (2) was initiated by the 
identification of the (–)-fragin (1) gene cluster, which was the first 
biosynthetic gene cluster encoding for a diazeniumdiolate 
compound. The (–)-fragin gene cluster consists of seven genes 
separated in two oppositely orientated operons (figure 1). The 
predicted functions of the corresponding proteins include a haem-
oxygenase for HamA, a cupin domain superfamily protein for 
HamB, a p-aminobenzoate  N-oxygenase for HamC, a non-
ribosomal peptide synthetase (NRPS)-like protein for HamD, a 
polyketide cyclase/dehydratase for HamE, a starter condensation 
domain for HamF, and an aminotransferase for HamG.[13] Based 
on the structure of (rac)-valdiazen (2) and (–)-fragin (1), L-valine 
(3) was hypothesized to be the substrate for their biosyntheses. 
Our suggestion is in agreement with a recent study performed on 
PvfC,[17] a homolog of HamD initially discovered in a 
Pseudomonas entomophila strain.[18] Li and coworkers identified 
the key residues of the active side, and demonstrated by 
bioinformatics and experimental studies that L-valine (3) is the 
initial substrate of the PvfC NRPS. Furthermore, our group 
investigated the p-aminobenzoate N-oxygenase enzyme HamC, 
a homologue of AurF.[19] HamC was produced, isolated and, 
similar to  AurF[19], shown to oxidize p-aminobenzoic acid into p-
nitrobenzoic acid.[13] Furthermore, preliminary experiments 
explored the origin of the terminal N atom of the diazeniumdiolate 
group and chromatographic evidence suggested it originated from 
nitrite. Recently, several reports indicated similar biosynthetic 
pathways[20,21]  for the diazeniumdiolate alanosine,[22] the diazo 
compounds cremeomycin[23-26] and kanamycin,[27] the pyridazine 
azamerone,[28] the N-hydroxytriazene,[29] and the hydrazide 
fosfazinomycin.[27,30]  
 
Figure 1. Constitution and configuration of the natural products (–)-fragin (1) 
and (rac)-valdiazen (2), and their biosynthetic gene cluster identified in the B. 
cenocepacia H111 genome. The diazeniumdiolate function group is highlighted 
in red and the predicted function of the genes is indicated in brackets. 
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In this study, we continued our biosynthetic investigations of 
(–)-fragin (1) with the determination of the initial substrate of the 
HamD NRPS and with the search for biosynthetic intermediates. 
Furthermore, we hypothesized that the biological activities of (–)-
fragin (1) required all chemical features present in the natural 
product. Several derivatives were designed, synthesized, and 
tested in order to experimentally corroborate these hypotheses. 
Our biosynthetic investigations started with the identification 
of the amino acid substrate of the NRPS complex HamD. In silico 
analysis of the HamD adenylation domain predicted 
phenylalanine (NRPSsp[31]) or leucine (antiSMASH 3.0[32] and 
NRPSpredictor 2[33]) to be the amino acid substrate. However, 
based on the structure of fragin, we proposed that either valine or 
leucine is the substrate of the HamD adenylation domain. This is 
supported by recently published data that identified valine as the 
amino acid substrate of PvfC, which has an identical 10 amino 
acid code in its adenylation domain to HamD.[17] To test valine 
incorporation into fragin, feeding experiments were performed 
using [U-13C5]-L-valine (4) and the supernatant was analysed by 
HRMS. The pseudomolecular ion [M+Na]+ with an m/z of 
301.2108 Da was detected, indicating the incorporation of five 
labelled C atoms into (–)-fragin (1). Relative quantification 
showed that 9.7 % of total fragin from this feeding experiment was 
isotopically labelled fragin (Scheme 1) suggesting that L-valine (3) 
is the initial substrate for HamD. 
  
Scheme 1. Feeding experiment with [U-13C5]-L-valine (4) demonstrated the 
incorporation of [U-13C5]-L-valine (4) into fragin [1,1,2,3,4-13C5]-fragin (5). 
We continued our investigation by identifying at which 
biosynthetic step the diazeniumdiolate group is formed. Due to 
the instability of this functional group, we first hypothesized that it 
could be formed late in the biosynthesis. Several possible 
intermediates were proposed, including different oxidation states 
of the amino or hydroxy group such as the amine 6, 
hydroxylamine 7, nitroso compound 8, oxime 9, nitro compound 
10, hydroxy compound 11 and keto derivative 12 (Scheme 2). 
 
Scheme 2. (–)-Fragin (1) biosynthesis proposal considering a late stage 
diazeniumdiolate formation. 
 
The amine 6 and hydroxylamine 7 derivatives were synthesized 
following a recently reported procedure.[13] Peptide coupling was 
performed with 1-amino-3-methylbutan-2-ol and octanoic acid 
using HATU to obtain the hydroxy compound 11, which was 
oxidized with the Dess-Martin periodinane (DMP) reagent into the 
ketone 12 and further reacted with NH2OH x HCl to obtain the 
oxime 9. An additional oxidation of the oxime 9 with meta-
chloroperoxybenzoic acid (mCPBA) led to the nitro compound 10 
and the oxidation of the hydroxylamine 7 gave the nitroso 
derivative 8 (Scheme 3).  
 
Scheme 3. Synthesis of biosynthetic proposed intermediates. a) DMP, CH2Cl2, 
4 h, 46%; b) NH2OH x HCl, NaOAc, MeOH, 85°C, 8 h, 44%; c) Urea, Na2HPO4, 
MeCN, reflux, 30 min, m-CPBA, reflux, 2 h, 54%; d) m-CPBA, CHCl3, 0°C, 2 h, 
RT, 1 h, 99%.  
The supernatants of the wild type and the previously reported 
mutant strains ∆hamA, ∆hamB, ∆hamC, ∆hamD, ∆hamE, ∆hamF, 
and ∆hamG[13] were extracted with CHCl3 and analyzed by HPLC-
MS using the synthesized derivatives as analytical standards. 
Interestingly, the oxime 9 was present in small amounts in the 
extract of the wild type strain (Supporting info), which however 
could also be formed during the decomposition of fragin.[10] 
However, none of the derivatives were detected in the extracts of 
the mutants. These results including the discovery and isolation 
of (rac)-valdiazen (2) suggested that the formation of the 
diazeniumdiolate occurred during an early step of the biosynthetic 
pathway. We proposed that L-valine (3) would be the initial 
substrate of the NRPS complex HamD and that the enzymes of 
unknown functions, HamA and HamE, and the N-oxygenase 
analog HamC would transform the amine into the 
diazeniumdiolate. This hypothesis is supported by the previous 
identification of several modifications occurring during chain 
elongation[34-36] and by recent investigations on alanosine 
biosynthesis.[22,37] The compound would be released as an 
aldehyde by the reductase domain of HamD and further reduced 
by the same enzyme to obtain (rac)-valdiazen (2). A similar 
biosynthetic pathway was proposed for the formation of 
myxochelins A and B involving a NRPS reductase domain 
performing two and four-electron reductions.[38] Furthermore, the 
presence of a biosynthetic intermediate that racemized was 
hypothesized due to the inverse configuration of the stereogenic 
center of (–)-fragin (1), when compared to its initial substrate L-
valine (3) and the isolation of (rac)-valdiazen (2) as a racemate. 
The possible intermediate 13 was proposed to racemize due to 
the presence of a reactive aldehyde, at the beta position of the 
diazeniumdiolate, which could interconvert to its enolate tautomer 
form. Finally, HamB, the aminotransferase HamG, and the starter 
condensation domain protein HamF would be involved in the last 




that these enzymes were not essential for the production of (rac)-
valdiazen (2) (Scheme 4).13 
 
 
Scheme 4. Biosynthesis proposal of the natural product (–)-fragin (1) and (rac)-
valdiazen (2) including the racemization via the aldehyde intermediate 13. 
Intrigued by the presence of the oxime 9 in the wild type strain, 
we decided to investigate the formation of the diazeniumdiolate 
on a model substrate. As it was hypothesized before, the 
diazeniumdiolate could be formed by reacting a hydroxylamine 
with an NO donor source. We treated the hydroxylamine 7 with 
sodium nitrite in an aq. methanol solution ensuring the solubility 
of the reagents and the reaction was analysed by HPLC-MS at 
the time of addition, after 3.5 h and after 7.6 h. The compounds 
were identified based on their mass and retention time using the 
internal standards synthesized above. Directly after the addition 
of the hydroxylamine 7 all the derivatives were already observed 
except for the nitro compound 10, which supported the notion that 
the formation of the diazeniumdiolate is a fast process. A 
decrease in the concentration of the hydroxylamine 7 and the 
nitroso compound 8, and a constant increase in the concentration 
of the oxime 9 and the nitro compound 10 would suggest that 10 
and 9 would constitute the final and more stable compounds. The 
concentration of (rac)-fragin (14) was first increased at the 3.5 h 
time point but then had dropped after 7.6 h, which was 
accompanied by an increase in the concentration of the oxime 9. 
Taking these results into account, we hypothesized that the 
hydroxylamine 7 is converted to the diazeniumdiolate (rac)-fragin 
(14) that decomposed into the oxime 9 and the nitro compound 
10 (Figure 2). Under these conditions, the major decomposition 
product detected was the oxime 9, which was also observed in 
the crude extract of the B. cenocepacia H111 wild type strain and 
was previously identified as a degradation product of fragin.[10] 
Using our model system, we hypothesize that the oxime 9 
observed in the wild type strain is a degradation product of fragin 
and not a biosynthetic intermediate.  
 
Figure 2. Chromatogram overlays of the reaction between the hydroxylamine 
and NaNO2 after the addition of the salt, after 3.5 h and after 7.6 h. 
In our previous study, (–)-fragin (1) was found to possess 
antifungal activity as well as antibacterial activity against Gram-
positive bacteria.[13] A structure-activity relationship (SAR) study 
was designed to determine which part for the compound is 
important for its potency and how alterations in its structure might 
affect the antibacterial and antifungal activity. (–)-Fragin (1) is 
composed of an acyl side chain and an amino acid part originating 
from L-valine (3) and possesses the diazeniumdiolate functional 
group. Our SAR strategy was designed to independently modify 
the two different parts of the compound and to evaluate the effect 
of the diazeniumdiolate functional group. 
 
Figure 3. SAR strategy on the modification of (–)-fragin (1). The green part 
highlights the amino acid part, the blue part the acyl moiety and the red part the 
diazeniumdiolate functional group.  
The effect on the acyl moiety length was first investigated with the 
synthesis of two derivatives possessing acyl side chains 
composed of 6 or 16 carbons. Furthermore, the amino acids 
alanine and leucine were selected as a smaller and larger 
aliphatic residue for the amino acid replacements for fragin. The 
previously synthesized ammonium salt 15 was coupled to the 
activated hexanoic acid for 16 and with hexadecanoic chloride for 
17, and the salts 18 and 19 were coupled to octanoyl chloride for 
20 and 21. The Fmoc of the compounds were deprotected, the 
amine was oxidized and a final treatment with isopentyl nitrite 





Scheme 5. Synthesis of fragin derivatives 22, 23, 24 and 25. a) hexanoyl 
chloride for 16, hexadecanoyl chloride for 17 and octanoyl chloride for 20 and 
21 DIPEA, DMAP, RT, 14 h, 92% for 16 75% for 17, 70% for 20; b) AlCl3, toluene, 
RT, 3.5 h 80% for 26, 45% for 27, 96% for 28 and 25% over 2 steps for 29; c) 
dibenzoylperoxide, K2HPO4, THF, RT, 21 h, 77% for 30, 43% for 31, 16% for 32 
and 42% for 33; d) N2H4 x H2O, EtOH, RT, 2.5 h; d) isopentyl nitrite, NH3(g), 
EtOH, RT, 0.5 h, 31% over 2 steps for 22, 52% over 2 steps for 23, 65% over 2 
steps for 24 and 38% over 2 steps form 25. Abbreviation: DIPEA: N,N-
diisopropylethylamine, DMAP: 4-dimethylaminopyridine and THF; 
tetrahydrofuran. 
(–)-Fragin (1) was methylated using dimethyl sulfate and sodium 
carbonate as a base to obtain O(2)Me-(–)-fragin (34). As reported 
previously, the oxygen at the O(2) position of the diazeniumdiolate 
was protected and gave a stable product (Scheme 6).[39] 
  
Scheme 6. Synthesis of O(2)Me-(–)-fragin (34). a) Na2CO3, Me2SO4, MeOH, 
0°C, 15 min, RT, 2.5 h, 71%. 
Inhibition of Gram-negative bacteria could only be observed for 
(–)-fragin (1) with the highest tested concentration (128 µg/ml) 
against E. coli, but not against our two other model organisms, 
Pseudomonas putida and Klebsiella oxytoca. A shorter acyl side 
chain with the derivative 22 was found to lower the activity against 
the Gram-positive bacteria but to retain the inhibition of E. coli. 
The inverse observation was made for the longer acyl side chain 
23 which retained the inhibition of Gram-positive bacteria but 
showed no more inhibition of E. coli. Interestingly, the shorter as 
well as the longer acyl side chain derivatives (22 and 23 
respectively) showed diminished or no antifungal activity (Figure 
4). The variation of the amino acid moiety with the derivatives 24 
and 25 showed the importance of the branched alkyl group for the 
activity against Bacillus cereus and Staphylococcus aureus. 
Antifungal activity was clearly diminished with the alanine 
derivative 24 while the leucine derivative 25 displayed only a weak 
reduction of the antifungal activity compared to 1. Finally, the 
methylated diazeniumdiolate (–)-fragin 34 did not display any 
antibacterial or antifungal activities highlighting the crucial role 
that this functional group plays in the bioactivity of fragin (Table 1 
and Figure 4).  
  
Table 1 Minimal inhibitory concentration of fragin and its derivatives 
against Gram-positive (B. cereus and S. aureus) and Gram-negative (P. 
putida, E. coli and K. oxytoca) bacteria.  
 B. cereus S. aureus P. putida E. coli K. oxytoca 
1 16 32 >128 128 >128 
22 128 >128 >128 128 >128 
23 32 32 >128 >128 >128 
24 64 128 >128 128 >128 
25 16 32 >128 128 >128 
34 >128 >128 >128 >128 >128 
The activities are reported in µg/mL. The experiments were performed in 
triplicate. The activities equal or lower than 32 µg/mL are highlighted in 
bold and in red. The compounds tested were (–)-fragin (1), the shorter acyl 
side chain 22, the longer acyl side chain 23, the alanine 24, the leucine 25 
derivatives, and the methyl protected (–)-fragin 34. 
 
Figure 4. Disc diffusion assays of (–)-fragin (1) and its derivatives 22, 23, 24, 
25 and 34 to determine their antifungal activity. Three different amounts (20 µg, 
40 µg and 80 µg) of each compound were tested. Representative pictures of 
antifungal spray assays against the fungus Fusarium solani are shown. 
In conclusion, the initial substrate of fragin biosynthesis was 
investigated using isotopically labeled [U-13C5]-L-valine (4) and an 
incorporation of all the 13C atoms of valine into fragin were 
observed by HRMS measurement. Furthermore, two possible 
biosynthetic models suggesting an early or late formation of the 
diazeniumdiolate functional group were proposed. Several 
biosynthetic intermediates, hypothesized in the case of a 
diazeniumdiolate late stage formation, were synthesized and 
used as analytical standards in the analysis of the wild type and 
mutant strain (∆hamA, ∆hamB, ∆hamC, ∆hamD, ∆hamE, ∆hamF, 
and ∆hamG) supernatants. Only the oxime 9 was detected in the 
wild type strain and was identified in a previous report as a 




diazeniumdiolate could be formed during an early stage of the 
biosynthesis.  
Additionally, a SAR study was performed on fragin in relation with 
its antibacterial and antifungal activity. Derivatives with a modified 
acyl side chain, a modified amino acid moiety and deactivation of 
the diazeniumdiolate were synthesized and their activities against 
the fungus F. solani and several  Gram-positive and Gram-
negative bacteria were evaluated. An eight C atom acyl side chain, 
an amino acid possessing an isopropyl group and an 
underivatized diazeniumdiolate were found to be essential to 
retain a good activity against Gram-positive bacteria. All the 
tested compounds possessed a weak potency against Gram-
negative bacteria and the derivatives with a long acyl side chain 
or a methylated diazeniumdiolate lost their activity. In contrast to 
antibacterial activity, we found that even minor structural changes 
of fragin greatly reduced its antifungal activity. 
Experimental Section 
The experimental procedures and the characterization of the compounds 
are found in the supporting information.  
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